Browse drugs

…ore changes from Baseline with DS-7011a and placebo^Conclusions DS-7011a was safe and well tolerated and showed favorable PK and initial…

…atients studied, 90(30%) underwent non-medical switch, Group 1 [RTX-O to RTX-B=68%; between biosimilars=32%]. Their mean (SD) age was…

…s received BLM after bDMARD. The main bDMARD use before BLM was rituximab in the 85.3% of patients. Baseline characteristics are summariz…

…es The REGENCY trial ( NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achie…

…te (TDF) (300 mg daily) plus lamivudine (3TC) (300 mg daily) or DTG (50 mg daily) in combination with TDF (300 mg once daily) plus …

…n for missing data. Pairwise comparisons were performed between IXE and tumour necrosis factor inhibitors (TNFi), secukinumab (SEC)…

…ed with multiple repetitions and added reconstitution steps for LyoP. Equipment (4, 10, 12), checks (8, 16, 16) and personnel requir…

…alcohol use disorder (AUD) receive medications for AUD, such as acamprosate. Medications for AUD may decrease progression of ALD. Challenge…

…ristics and outcomes of patients with T2D and CKD who initiated SGLT2i or GLP-1 RA in China. The results are important for understandi…

…t related adverse events was 66.7% (269 of 403 patients) in the carboplatin arm and 55.0% (222 of 404 patients) in the control arm. No trea…

…imed to compare the efficacy and safety of iguratimod (IGU) and hydroxychloroquine (HCQ) in patients with active primary Sjögren’s syndrome (pSS).…

…tenosis rates were lower with ticagrelor (5% vs 21%).Conclusion Ticagrelor 60 mg for DAPT in intracranial stenting is safe and effective. …